SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:prod.swepub.kib.ki.se:150619853"
 

Search: id:"swepub:oai:prod.swepub.kib.ki.se:150619853" > Prevalence, Charact...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Escobar, C (author)

Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-09-02
  • MDPI AG,2022

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:150619853
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:150619853URI
  • https://doi.org/10.3390/jcm11175199DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Objective: To estimate the prevalence, incidence, and describe the characteristics and management of patients with heart failure with preserved (HFpEF), mildly reduced (HFmrEF), and reduced ejection fraction (HFrEF) in Spain. Methods: Adults with ≥1 inpatient or outpatient HF diagnosis between 1 January 2013 and 30 September 2019 were identified through the BIG-PAC database. Annual incidence and prevalence by EF phenotype were estimated. Characteristics by EF phenotype were described in the 2016 and 2019 HF prevalent cohorts and outcomes in the 2016 HF prevalent cohort. Results: Overall, HF incidence and prevalence were 0.32/100 person-years and 2.34%, respectively, but increased every year. In 2019, 49.3% had HFrEF, 38.1% had HFpEF, and 4.3% had HFmrEF (in 8.3%, EF was not available). Compared with HFrEF, patients with HFpEF were largely female, older, and had more atrial fibrillation but less atherosclerotic cardiovascular disease. Among patients with HFrEF, 76.3% were taking renin-angiotensin system inhibitors, 69.5% beta-blockers, 36.8% aldosterone antagonists, 12.5% sacubitril/valsartan and 6.7% SGLT2 inhibitors. Patients with HFpEF and HFmrEF took fewer HF drugs compared to HFrEF. Overall, the event rates of HF hospitalization were 231.6/1000 person-years, which is more common in HFrEF patients. No clinically relevant differences were found in patients with HFpEF, regardless EF (50- < 60% vs. ≥60%). Conclusions: >2% of patients have HF, of which around 50% have HFrEF and 40% have HFpEF. The prevalence of HF is increasing over time. Clinical characteristics by EF phenotype are consistent with previous studies. The risk of outcomes, particularly HF hospitalization, remains high, likely related to insufficient HF treatment.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Palacios, B (author)
  • Varela, L (author)
  • Gutierrez, M (author)
  • Duong, M (author)
  • Chen, HT (author)
  • Justo, NKarolinska Institutet (author)
  • Cid-Ruzafa, J (author)
  • Hernandez, I (author)
  • Hunt, PR (author)
  • Delgado, JF (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:Journal of clinical medicine: MDPI AG11:172077-0383

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view